nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—bile duct cancer	0.83	1	CbGaD
Thalidomide—Lenalidomide—PTGS2—bile duct cancer	0.00436	0.518	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—bile duct cancer	0.00405	0.482	CrCbGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—bile duct cancer	0.000151	0.000936	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—bile duct cancer	0.000151	0.000935	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000151	0.000935	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KRAS—bile duct cancer	0.000151	0.000934	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—NRAS—bile duct cancer	0.00015	0.000932	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RNF43—bile duct cancer	0.00015	0.000932	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MET—bile duct cancer	0.00015	0.000928	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SMAD4—bile duct cancer	0.000149	0.000923	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—HRAS—bile duct cancer	0.000148	0.00092	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—bile duct cancer	0.000148	0.000919	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—bile duct cancer	0.000147	0.000914	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—bile duct cancer	0.000147	0.000909	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000145	0.0009	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.000145	0.000899	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000145	0.000898	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000144	0.000895	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—KRAS—bile duct cancer	0.000143	0.000887	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RNF43—bile duct cancer	0.000143	0.000884	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—bile duct cancer	0.000142	0.00088	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—HRAS—bile duct cancer	0.000142	0.000878	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—HRAS—bile duct cancer	0.000141	0.000874	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—HRAS—bile duct cancer	0.00014	0.00087	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TGFB1—bile duct cancer	0.00014	0.000866	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL6—bile duct cancer	0.00014	0.000866	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—bile duct cancer	0.00014	0.000866	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—KRAS—bile duct cancer	0.000139	0.000864	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—bile duct cancer	0.000139	0.000863	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—bile duct cancer	0.000139	0.000862	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000138	0.000858	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—bile duct cancer	0.000138	0.000854	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.000138	0.000853	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—bile duct cancer	0.000138	0.000853	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—bile duct cancer	0.000137	0.000849	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000137	0.000849	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000136	0.000844	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—bile duct cancer	0.000136	0.000841	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bile duct cancer	0.000135	0.000838	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bile duct cancer	0.000135	0.000838	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—bile duct cancer	0.000135	0.000837	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—bile duct cancer	0.000134	0.000833	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—bile duct cancer	0.000134	0.000828	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000132	0.000821	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000131	0.000814	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—bile duct cancer	0.000131	0.000814	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000131	0.000814	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—bile duct cancer	0.000131	0.000813	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—bile duct cancer	0.00013	0.000807	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—KRAS—bile duct cancer	0.000129	0.000802	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—bile duct cancer	0.000129	0.000801	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000129	0.0008	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—NRAS—bile duct cancer	0.000129	0.000799	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—bile duct cancer	0.000128	0.000796	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—bile duct cancer	0.000128	0.000794	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	0.000128	0.000791	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—bile duct cancer	0.000127	0.00079	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000126	0.000782	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FAR2—bile duct cancer	0.000126	0.000781	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—bile duct cancer	0.000126	0.000779	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000126	0.000779	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—bile duct cancer	0.000126	0.000779	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—bile duct cancer	0.000125	0.000774	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—bile duct cancer	0.000125	0.000772	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000124	0.000766	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000123	0.000766	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—bile duct cancer	0.000123	0.000762	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—bile duct cancer	0.000123	0.00076	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—bile duct cancer	0.000122	0.000759	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—bile duct cancer	0.000122	0.000758	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—bile duct cancer	0.000122	0.000754	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000119	0.000736	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—bile duct cancer	0.000118	0.000734	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—bile duct cancer	0.000117	0.000728	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000117	0.000724	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000116	0.000721	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—bile duct cancer	0.000115	0.000713	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FAR2—bile duct cancer	0.000115	0.000712	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—bile duct cancer	0.000115	0.000711	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MET—bile duct cancer	0.000114	0.000707	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—bile duct cancer	0.000113	0.0007	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—bile duct cancer	0.000112	0.000697	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—bile duct cancer	0.000112	0.000692	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—bile duct cancer	0.000111	0.000691	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000111	0.00069	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KRAS—bile duct cancer	0.000111	0.000688	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.00011	0.000684	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ERBB2—bile duct cancer	0.000109	0.000678	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—bile duct cancer	0.000109	0.000677	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	0.000108	0.000673	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000108	0.000671	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—IDH2—bile duct cancer	0.000107	0.000661	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KRAS—bile duct cancer	0.000105	0.000653	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—bile duct cancer	0.000105	0.000652	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000104	0.000643	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RNF43—bile duct cancer	0.000101	0.000627	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FAR2—bile duct cancer	9.81e-05	0.000609	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HGF—bile duct cancer	9.76e-05	0.000605	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB2—bile duct cancer	9.66e-05	0.000599	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—bile duct cancer	9.62e-05	0.000597	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—bile duct cancer	9.59e-05	0.000595	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—bile duct cancer	9.51e-05	0.00059	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—bile duct cancer	9.43e-05	0.000585	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—bile duct cancer	9.43e-05	0.000585	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—bile duct cancer	9.39e-05	0.000582	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFBR2—bile duct cancer	9.31e-05	0.000577	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB2—bile duct cancer	9.28e-05	0.000575	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HGF—bile duct cancer	9.26e-05	0.000574	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	9.25e-05	0.000574	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—bile duct cancer	9.18e-05	0.000569	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—IDH1—bile duct cancer	9.17e-05	0.000569	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB2—bile duct cancer	9.17e-05	0.000569	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—bile duct cancer	9.03e-05	0.00056	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—bile duct cancer	8.95e-05	0.000555	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SMAD4—bile duct cancer	8.81e-05	0.000546	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB2—bile duct cancer	8.81e-05	0.000546	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IDH1—bile duct cancer	8.7e-05	0.000539	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—bile duct cancer	8.64e-05	0.000535	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—bile duct cancer	8.56e-05	0.000531	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—IDH2—bile duct cancer	8.47e-05	0.000525	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ERBB2—bile duct cancer	8.34e-05	0.000517	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—bile duct cancer	8.33e-05	0.000516	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—IDH2—bile duct cancer	7.97e-05	0.000494	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—IDH2—bile duct cancer	7.96e-05	0.000493	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	7.8e-05	0.000483	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—bile duct cancer	7.74e-05	0.00048	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	7.64e-05	0.000474	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—bile duct cancer	7.58e-05	0.00047	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—IDH2—bile duct cancer	7.52e-05	0.000466	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—bile duct cancer	7.35e-05	0.000456	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—IDH1—bile duct cancer	7.28e-05	0.000452	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	7.22e-05	0.000448	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—bile duct cancer	7.17e-05	0.000444	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—bile duct cancer	7.15e-05	0.000443	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—bile duct cancer	7.06e-05	0.000438	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—bile duct cancer	6.98e-05	0.000433	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFBR2—bile duct cancer	6.87e-05	0.000426	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—IDH1—bile duct cancer	6.86e-05	0.000425	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—IDH1—bile duct cancer	6.84e-05	0.000424	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—bile duct cancer	6.7e-05	0.000415	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—bile duct cancer	6.7e-05	0.000415	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNAS—bile duct cancer	6.63e-05	0.000411	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—bile duct cancer	6.56e-05	0.000407	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFBR2—bile duct cancer	6.52e-05	0.000404	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMAD4—bile duct cancer	6.5e-05	0.000403	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—IDH1—bile duct cancer	6.46e-05	0.000401	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—bile duct cancer	6.43e-05	0.000399	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	6.42e-05	0.000398	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—bile duct cancer	6.36e-05	0.000394	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—bile duct cancer	6.34e-05	0.000393	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—bile duct cancer	6.33e-05	0.000392	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNAS—bile duct cancer	6.29e-05	0.00039	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMAD4—bile duct cancer	6.17e-05	0.000382	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—IDH2—bile duct cancer	6.15e-05	0.000381	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—bile duct cancer	6.1e-05	0.000378	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—bile duct cancer	6.09e-05	0.000378	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—bile duct cancer	6.08e-05	0.000377	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC5A5—bile duct cancer	6.05e-05	0.000375	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—bile duct cancer	6e-05	0.000372	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—bile duct cancer	5.89e-05	0.000365	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—bile duct cancer	5.83e-05	0.000361	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—bile duct cancer	5.78e-05	0.000358	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—bile duct cancer	5.77e-05	0.000357	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5.67e-05	0.000352	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—bile duct cancer	5.63e-05	0.000349	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—IDH2—bile duct cancer	5.61e-05	0.000348	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—bile duct cancer	5.46e-05	0.000338	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—bile duct cancer	5.38e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—bile duct cancer	5.34e-05	0.000331	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—IDH1—bile duct cancer	5.29e-05	0.000328	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—bile duct cancer	5.17e-05	0.00032	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—bile duct cancer	5.15e-05	0.000319	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—bile duct cancer	5.1e-05	0.000316	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—bile duct cancer	4.93e-05	0.000306	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—bile duct cancer	4.9e-05	0.000304	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—bile duct cancer	4.88e-05	0.000303	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—IDH1—bile duct cancer	4.82e-05	0.000299	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—bile duct cancer	4.82e-05	0.000299	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC5A5—bile duct cancer	4.81e-05	0.000298	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—IDH2—bile duct cancer	4.79e-05	0.000297	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNAS—bile duct cancer	4.7e-05	0.000292	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—bile duct cancer	4.64e-05	0.000288	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFBR2—bile duct cancer	4.62e-05	0.000287	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC5A5—bile duct cancer	4.52e-05	0.00028	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC5A5—bile duct cancer	4.51e-05	0.00028	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—bile duct cancer	4.44e-05	0.000275	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD4—bile duct cancer	4.38e-05	0.000271	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—bile duct cancer	4.28e-05	0.000265	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC5A5—bile duct cancer	4.26e-05	0.000264	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—IDH1—bile duct cancer	4.12e-05	0.000256	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—bile duct cancer	4.06e-05	0.000252	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	4e-05	0.000248	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—bile duct cancer	3.9e-05	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—bile duct cancer	3.75e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNAS—bile duct cancer	3.73e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—bile duct cancer	3.7e-05	0.00023	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—bile duct cancer	3.69e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—bile duct cancer	3.64e-05	0.000226	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNAS—bile duct cancer	3.51e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNAS—bile duct cancer	3.51e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—bile duct cancer	3.5e-05	0.000217	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC5A5—bile duct cancer	3.49e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—bile duct cancer	3.49e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—bile duct cancer	3.45e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—bile duct cancer	3.42e-05	0.000212	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNAS—bile duct cancer	3.31e-05	0.000205	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	3.27e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—bile duct cancer	3.26e-05	0.000202	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—bile duct cancer	3.23e-05	0.0002	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC5A5—bile duct cancer	3.18e-05	0.000197	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—bile duct cancer	3.13e-05	0.000194	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—bile duct cancer	3.12e-05	0.000194	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—bile duct cancer	3e-05	0.000186	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	2.98e-05	0.000185	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—bile duct cancer	2.97e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—bile duct cancer	2.96e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—bile duct cancer	2.85e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—bile duct cancer	2.77e-05	0.000172	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—bile duct cancer	2.74e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—bile duct cancer	2.72e-05	0.000169	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAS—bile duct cancer	2.71e-05	0.000168	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—bile duct cancer	2.63e-05	0.000163	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—bile duct cancer	2.63e-05	0.000163	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—bile duct cancer	2.57e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	2.55e-05	0.000158	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—bile duct cancer	2.53e-05	0.000157	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—bile duct cancer	2.52e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAS—bile duct cancer	2.47e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—bile duct cancer	2.45e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—bile duct cancer	2.44e-05	0.000151	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—bile duct cancer	2.39e-05	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—bile duct cancer	2.38e-05	0.000148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—bile duct cancer	2.26e-05	0.00014	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—bile duct cancer	2.12e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAS—bile duct cancer	2.11e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—bile duct cancer	2.03e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—bile duct cancer	2.01e-05	0.000125	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—bile duct cancer	1.94e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—bile duct cancer	1.92e-05	0.000119	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—bile duct cancer	1.89e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—bile duct cancer	1.88e-05	0.000117	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—bile duct cancer	1.86e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—bile duct cancer	1.84e-05	0.000114	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—bile duct cancer	1.78e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—bile duct cancer	1.73e-05	0.000107	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—bile duct cancer	1.7e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—bile duct cancer	1.6e-05	9.94e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—bile duct cancer	1.46e-05	9.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—bile duct cancer	1.36e-05	8.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—bile duct cancer	1.33e-05	8.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—bile duct cancer	1.3e-05	8.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—bile duct cancer	1.13e-05	7.04e-05	CbGpPWpGaD
